Looks like I mixed the numbers in two msgs, sorry, no offense, mdr posted the "No of $1B" total value. Hope my logic for a >$6 works out; we're after the same goal...."share price maximization"... Finance 301. Now we watch.
If you're responding to my post, I never said anything of the sort. I do remember someone else posting those numbers and I too thought they were crazy, too ridiculous to even comment on them. I say 5-6 because I cant remember any buyout of a microcap going for more than 100% of current SP. The most ridiculous buyout I remember is when merck bought Sirna for $1B for unproven technology. That was 100-110% premium above the stock price at the time. Merck has since cancelled their RNAi efforts, too funny.Of course I'd be happy with Riche buying CRIS for more than $6/share! GLTAL
I have been following Curis since its inception in 2000; do not recall DP ever cancelling a presentation since he became a CEO; one time Grey filled in for him; impossible to read the tea leaves on this one; as evidenced by Curis' announcement that the two trials had been cancelled last June. No one foresaw it, most of all DP who up until the announcement made statements leading one to conclude he genuinely believed the trials were going forward. Will see shortly what Roche has in mind, but if it is a buy out it has done a masterful job of concealing it because the stock is quiet as a millpond.
Did you register and listen to the webcast? I'm guessing not because there is nothing listed for Curis at 2:30 on Monday. It's just a blank square with all the other squares artound it filled in with other presenters. CRIS definitely did not present yesterday.
With everyone sitting on pins and needles waiting for the news, I can't help but speculate IF it means news is imminent? I'm sure it is meaningless and has no impact on the news we are expecting but I can't help but wonder. By the way, who is WSJ?
GLTA and let's hope we don't have to wait much longer for the long anticipated study results and here's to hoping they are spectacular.